Amylyx Pharmaceuticals AMLX
Valuation
Multiples measured against the stock's own five-year history
Near the bottom of its 5-year range · 3rd percentile, 5-year average 23.9x
Above its usual level · 65th percentile, 5-year average 4.5x
#4404 of 5330 stocks by PB (1 = cheapest)
Near the bottom of its 5-year range · 3rd percentile, 5-year average -516.6x
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 5.17 | – | 4.48 | 65% (pricier than usual) | #4404 of 5330 (1 = cheapest) |
| PE | -21.18 | -22.39 | 23.86 | 3% (cheaper than usual) | – |
| PS | -5,855.90 | 319.12 | -516.58 | 3% (cheaper than usual) | – |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on AMLX.
Sign in to join the discussion.